Douglas M. Lankler - Feb 26, 2022 Form 4 Insider Report for PFIZER INC (PFE)

Role
Executive Vice President
Signature
Susan E. Grant, by power of atty., for Douglas M. Lankler
Stock symbol
PFE
Transactions as of
Feb 26, 2022
Transactions value $
-$857,200
Form type
4
Date filed
3/1/2022, 03:03 PM
Previous filing
Feb 25, 2022
Next filing
May 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PFE Common Stock Options Exercise $1.99M +77.7K +80.28% $25.60 175K Feb 26, 2022 Direct F1
transaction PFE Common Stock Tax liability -$1.01M -21.1K -12.12% $47.72 153K Feb 26, 2022 Direct F2, F3
transaction PFE Common Stock Tax liability -$1.84M -36.3K -23.66% $50.64 117K Feb 26, 2022 Direct F4, F5
holding PFE Common Stock 1.68K Feb 26, 2022 By Rule 16b-3 Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PFE Stock Appreciation Rights Options Exercise $0 -77.7K -100% $0.00* 0 Feb 26, 2022 Common Stock 77.7K $25.60 Direct
transaction PFE Stock Appreciation Rights Award $0 +10.6K $0.00 10.6K Feb 28, 2022 Common Stock 10.6K $46.94 Direct F6
transaction PFE Stock Appreciation Rights Award $0 +9.29K $0.00 9.29K Feb 28, 2022 Common Stock 9.29K $46.94 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3 Price is the closing price of Pfizer common stock on February 25, 2022.
F4 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F5 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
F6 The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
F7 The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.